The characterization of these cells and models of resistance post CDK4/6 inhibitor + ET treatment highlight the potential for novel therapeutic approaches to overcome resistance to CDK4/6i + ET in HR+, HER2− breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.